Vincent Castonguay
Chercheur associé
Axe Oncologie
Dernières nouvelles
Centre de recherche
Le Centre de recherche du CHU de Québec sur le point de doubler son volume d’études cliniques précoces
Centre de recherche
Vers les traitements de demain avec la recherche clinique de phases 1 et 2 en hémato-oncologie
Centre de recherche
Vers les traitements de demain avec la recherche clinique de phases 1 et 2 en hémato-oncologie
Publications
Voir tout-
article Lorusso D, Colombo N, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera M, Samouëlian V, Castonguay V, Arkhipov A, Li K, Toker S, Tekin C, Tewari KS, Monk BJ
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
Ann Oncol 36 (1), 2025.
-
article Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomize…
JAMA Oncol 10 (2), 2024.
-
article Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
ESMO Open 9 (12), 2024.
Projets
- A Phase II, Multicentre, Open-label,[...]Efficacy and Safety of Datopotamab Deruxtecan(Dato-DXd) as Monotherapy[...]with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours(TROPION-PanTumor03)(sub-study 6:Bladder), du 2023-12-06 au 2028-12-25
- A Phase Ill Randomized, Open-Label,...Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative...Muscle Invasive Bladder Cancer (VOLGA)... , du 2023-08-23 au 2029-12-25